A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Imatinib (Primary) ; Infigratinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 14 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 02 Jun 2017 This trial has been amended to allow an alternative dosing schedule, as reported in an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.